Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Serrapeptase and Reduced Breast Engorgement

Safety in these studies

Overall tolerabilityNo significant differenceno women experienced adverse events in any of the groups receiving serrapeptase, protease or placebo (low-certainty evidence)
No women experienced adverse events in any of the groups receiving serrapeptase, protease or placebo (low-certainty evidence).
from: Treatments for breast engorgement during lactation.

1 of 1 paper

Treatments for breast engorgement during lactation.
- 2020-09-18
- Systematic Review · n = 2,170
- The Cochrane database of systematic reviews 2020(9)
- - Irena Zakarija-Grkovic
  - Fiona Stewart
- PubMed: 32944940
- DOI: 10.1002/14651858.cd006946.pub4
3 Insights on
- Reduced Breast Engorgement
- High evidence
- Clinical
serrapeptase may reduce the risk of engorgement compared to placebo (RR 0.36, 95% CI 0.14 to 0.88; 59 women; low-certainty evidence)
Effect
Beneficial
Effect size
Large
Significant
Yes